Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer

被引：0
|
作者：
Shuxia Qin
Lidan Yi
Sini Li
Chongqing Tan
Xiaohui Zeng
Liting Wang
Ye Peng
Xiaomin Wan
机构：
[1] Central South University,Department of Pharmacy, The Second Xiangya Hospital
[2] Central South University,Xiangya Nursing School
[3] Central South University,PET
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Atezolizumab; Bladder cancer; Cost-effectiveness; Markov model; Urothelial carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3399 / 3408
页数：9
相关论文
共 50 条
  • [41] Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France
    Porte, Fanny
    Granghaud, Anna
    Chang, Jane
    Kearney, Mairead
    Morel, Aya
    Plessala, Ingrid
    Cawston, Helene
    Roiz, Julie
    Xiao, Ying
    Solbes, Marie-Noelle
    Lambert, Prisca
    Ravaud, Alain
    Loriot, Yohann
    Thiery-Vuillemin, Antoine
    Levy, Pierre
    PLOS ONE, 2024, 19 (05):
  • [42] Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza Ahmed Mohamed
    Saleh, Khaldoon
    Tashkandi, Emad
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 67 - 75
  • [43] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.
    Attard, Cheryl L.
    Brown, Stephen
    Alloul, Karine
    Moore, Malcolm J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [44] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Cheng, Rihua
    Zhou, Zhen
    Liu, Qiao
    ADVANCES IN THERAPY, 2023, 40 (10) : 4298 - 4309
  • [45] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
    Rihua Cheng
    Zhen Zhou
    Qiao Liu
    Advances in Therapy, 2023, 40 : 4298 - 4309
  • [46] Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China
    Lin, Nanlong
    Chen, Shiting
    Zheng, Zhiwei
    Song, Xiaobing
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 205 - 213
  • [47] Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer
    Berry, Kristin
    Bensink, Mark Eliot
    Musa, Zahra
    Shankaran, Veena
    Lin, Edward H.
    Ladabaum, Uri
    Bodnar, Carolyn
    Birt, Michael
    Ramsey, Scott David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Cost-effectiveness analysis of sintilimab plus chemotherapy versus camrelizumab plus chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China
    Rui, Mingjun
    Fei, Zhengyang
    Wang, Yingcheng
    Zhang, Xueke
    Ma, Aixia
    Sun, Haikui
    Li, Hongchao
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 618 - 629
  • [49] Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.
    Tural, Deniz
    Olmez, Omer Fatih
    Sumbul, Ahmet Taner
    Artac, Mehmet
    Ozhan, Nail
    Akar, Emre
    Cakar, Burcu
    Kostek, Osman
    Ekenel, Meltem
    Coskun, Hasan Senol
    Selcukbiricik, Fatih
    Keskin, Ozge
    Turkoz, Fatma Paksoy
    Oruc, Kerem
    Bayram, Selami
    Yilmaz, Ugur
    Bilgetekin, Irem
    Yildiz, Birol
    Sendur, Mehmet Ali Nahit
    Erman, Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [50] COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMBINATION THERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER IN THE UNITED STATES
    Criss, Steven
    Mooradian, Meghan
    Watson, Tina
    Gainor, Justin
    Reynolds, Kerry
    Kong, Chung Yin
    MEDICAL DECISION MAKING, 2020, 40 (01) : E353 - E354
12345